| Stereochemistry | RACEMIC |
| Molecular Formula | C9H11N |
| Molecular Weight | 133.1903 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H]1C[C@H]1C2=CC=CC=C2
InChI
InChIKey=AELCINSCMGFISI-DTWKUNHWSA-N
InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m0/s1
Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. Tranylcypromine has being marketed under original trade name Parnate, indicated for the treatment of major depressive episode without melancholia. Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.
CNS Activity
Originator
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
PubMed
Patents
Sample Use Guides
The usual effective dosage is 30 mg per day, usually given in divided doses. If there are no
signs of improvement after a reasonable period (up to 2 weeks), then the dosage may be
increased in 10 mg per day increments at intervals of 1 to 3 weeks; the dosage range may be
extended to a maximum of 60 mg per day from the usual 30 mg per day.
Route of Administration:
Oral
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
